Related references
Note: Only part of the references are listed.Cancer Statistics, 2015
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
A multicenter randomized, open-label, proof-of-concept, phase II trial comparing gemcitabine with and without IMM-101 in advanced pancreatic cancer.
Angus George Dalgleish
JOURNAL OF CLINICAL ONCOLOGY (2015)
Induced PD-L1 Expression Mediates Acquired Resistance to Agonistic Anti-CD40 Treatment
Alfred Zippelius et al.
CANCER IMMUNOLOGY RESEARCH (2015)
The ever-expanding immunomodulatory role of calreticulin in cancer immunity
Marco de Bruyn et al.
FRONTIERS IN ONCOLOGY (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer
M. Aglietta et al.
ANNALS OF ONCOLOGY (2014)
P53, hTERT, WT-1, and VEGFR2 are the most suitable targets for cancer vaccine therapy in HLA-A24 positive pancreatic adenocarcinoma
Takeshi Terashima et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies
K. Sideras et al.
CANCER TREATMENT REVIEWS (2014)
Pancreatic Cancer-Induced Cachexia Is Jak2-Dependent in Mice
Marine Gilabert et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2014)
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial
Gary Middleton et al.
LANCET ONCOLOGY (2014)
Pancreatic cancer, treatment options, and GI-4000
Marion L. Hartley et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
CD4+ T Lymphocyte Ablation Prevents Pancreatic Carcinogenesis in Mice
Yaqing Zhang et al.
CANCER IMMUNOLOGY RESEARCH (2014)
The Carcinoma-Associated Fibroblast Expressing Fibroblast Activation Protein and Escape from Immune Surveillance
Douglas T. Fearon
CANCER IMMUNOLOGY RESEARCH (2014)
Cancer mortality in Europe, 2005-2009, and an overview of trends since 1980
C. Bosetti et al.
ANNALS OF ONCOLOGY (2013)
Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients
Hidekazu Kameshima et al.
CANCER SCIENCE (2013)
A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2013)
Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer The CONKO-001 Randomized Trial
Helmut Oettle et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
Rikke B. Holmgaard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Addition of Algenpantucel-L Immunotherapy to Standard Adjuvant Therapy for Pancreatic Cancer: a Phase 2 Study
Jeffrey M. Hardacre et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Targeting CXCL12 from FAP-expressing carcinomaassociated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer
Christine Feig et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Immunotherapy updates in pancreatic cancer: are we there yet?
Krishna Soujanya Gunturu et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2013)
Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients
Ryuji Okuyama et al.
ONCOIMMUNOLOGY (2013)
A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer
Yefei Rong et al.
CLINICAL AND EXPERIMENTAL MEDICINE (2012)
A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction
Dung T. Le et al.
CLINICAL CANCER RESEARCH (2012)
Fluorouracil-based Chemoradiation with Either Gemcitabine or Fluorouracil Chemotherapy after Resection of Pancreatic Adenocarcinoma: 5-Year Analysis of the US Intergroup/RTOG 9704 Phase III Trial
William F. Regine et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer
Marina Lesina et al.
CANCER CELL (2011)
Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13
Rachel F. Gabitass et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Potential targets for pancreatic cancer immunotherapeutics
Lindzy F. Dodson et al.
IMMUNOTHERAPY (2011)
Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras
Synne Weden et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-κB-Dependent Manner
Neta Erez et al.
CANCER CELL (2010)
Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer
Motoki Miyazawa et al.
CANCER SCIENCE (2010)
Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein-α
Matthew Kraman et al.
SCIENCE (2010)
The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors
Michael Hedvat et al.
CANCER CELL (2009)
Molecular mechanism and function of CD40/CD40L engagement in the immune system
Raul Elgueta et al.
IMMUNOLOGICAL REVIEWS (2009)
The Galα1,3Galβ1,4GlcNAc-R (α-Gal) epitope:: A carbohydrate of unique evolution and clinical relevance
Bruce A. Macher et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS (2008)
Cancer-associated stroma fibroblasts promote pancreatic tumor progression
Rosa F. Hwang et al.
CANCER RESEARCH (2008)
Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: A pilot study of safety, feasibility, and immune activation
Dan Laheru et al.
CLINICAL CANCER RESEARCH (2008)
B7-H1 up-regulated expression in human pancreatic carcinoma tissue associates with tumor progression
Lei Geng et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2008)
Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection
Agnes Witkiewicz et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2008)
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
Sian Jones et al.
SCIENCE (2008)
Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer
Howard L. Kaufman et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2007)
A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma
Robert G. Maki et al.
DIGESTIVE DISEASES AND SCIENCES (2007)
Calreticulin exposure dictates the immunogenicity of cancer cell death
Michel Obeid et al.
NATURE MEDICINE (2007)
Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer
Takeo Nomi et al.
CLINICAL CANCER RESEARCH (2007)
Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study
S. L. Bernhardt et al.
BRITISH JOURNAL OF CANCER (2006)
Clinical roles of increased populations of Foxp3+CD4+ T cells in peripheral blood from advanced pancreatic cancer patients
Tetsuya Ikemoto et al.
PANCREAS (2006)
Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin
Marion Wobser et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinorna and its premalignant lesions
Nobuyoshi Hiraoka et al.
CLINICAL CANCER RESEARCH (2006)
The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor ζ-chain and induce a regulatory phenotype in naive T cells
Francesca Fallarino et al.
JOURNAL OF IMMUNOLOGY (2006)
Effective treatment of preexisting melanoma with whole cell vaccines expressing α(1,3)-galactosyl epitopes
GR Rossi et al.
CANCER RESEARCH (2005)
High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients
FH Schmitz-Winnenthal et al.
CANCER RESEARCH (2005)
Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response
AM Ercolini et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
CD8(+) tumor-infiltrating lymphocytes together with CD4(+) tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma
A Fukunaga et al.
PANCREAS (2004)
Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation
R Meisel et al.
BLOOD (2004)
Inflammatory cells contribute to the generation of an angiogenic phenotype in pancreatic ductal adenocarcinoma
I Esposito et al.
JOURNAL OF CLINICAL PATHOLOGY (2004)
Mucin gene (MUC1) transfected dendritic cells as vaccine:: results of a phase I/II clinical trial
G Pecher et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2002)
Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase
DH Munn et al.
SCIENCE (2002)
Differential expression of gastrin, cholecystokinin-A and cholecystokinin-B receptor mRNA in human pancreatic cancer cell lines
HJ Monstein et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2001)
Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant:: Clinical and immunological responses in patients with pancreatic adenocarcinoma
MK Gjertsen et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immune activation
EM Jaffee et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)